The dose-findings studies reported here not only documented the superior efficacy of GLP1/E in the management of metabolic alterations in our obese PCOS model, including lowering body weight and adiposity, as well as improvement of glucose handling and insulin resistance, but also highlighted a non-monotonic effect of this dual agonist in PNA mice, with optimal effects being achieved with submaximal doses
Methods The current study involves the fusion of a native or mutant GLP-1 (30 residues) with an HSA-binding DARPin (123 residues) via a rigid helical linker (15 residues) to create fusion proteins (168 residues) resistant to DPP-IV and, or trypsin with extended half-lives using structural modeling, which are subsequently characterized using MD simulation and molecular docking analyses
Its a clear example of the Price-Safety Trap, where low up-front cost hides the lack of real medical care or proven results
B202313016776), Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy Department (No.CPA-Z05-ZC-2024-003) and Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University
a higher 2.4 mg dose in comparison with matched placebos over 68 weeks in 1210 participants (2)
Proc Natl Acad Sci U S A (2009) 106:128590
